Formulation: A neat liquid
Formal Name: 1-[(1R)-1-(phenyl-d5)ethyl]1H-imidazole-5-carboxylic acid ethyl ester
Purity: ≥99% deuterated forms (d1-d5)
Formula Markup: C14H11D5N2O2
Formula Weight: 249,3
Shelf life (days): 1460
Notes: Etomidate-d5 is intended for use as an internal standard for the quantification of etomidate by GC- or LC-MS. Etomidate is a general anesthetic.{66602} It selectively binds to GABAA receptors over voltage-gated sodium channels (Nav) and L-type voltage-gated calcium channels (Cav; IC50s = 15.7, 387, and 950 µM, respectively).{25312} Etomidate also inhibits the cytochrome P450 (CYP) isoforms CYP11B1 and CYP11B2 (IC50s = 0.5 and 0.1 nM, respectively), enzymes involved in cortisol and aldosterone biosynthesis, respectively.{69726} It inhibits the production of deoxycortisol and 17α-hydroxy progesterone (Item No. 33154) induced by adrenocorticotropic hormone (ACTH) in dispersed adrenocortical cells isolated from patients with Cushing’s syndrome.{69727} Etomidate (3 mg/kg) induces anesthesia and increases the minimum convulsive dose of pentylenetetrazole during the recovery period, but also induces myoclonus, in mice.{66602} Formulations containing etomidate have been used as general anesthetics.